These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 9166461

  • 1. Tumor angiogenesis in women with node-positive breast cancer.
    Folkman J.
    Cancer J Sci Am; 1995; 1(2):106-8. PubMed ID: 9166461
    [No Abstract] [Full Text] [Related]

  • 2. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.
    Gasparini G, Barbareschi M, Boracchi P, Verderio P, Caffo O, Meli S, Dalla Palma P, Marubini E, Bevilacqua P.
    Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466
    [Abstract] [Full Text] [Related]

  • 3. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G, Barbareschi M, Doglioni C, Palma PD, Mauri FA, Boracchi P, Bevilacqua P, Caffo O, Morelli L, Verderio P.
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [Abstract] [Full Text] [Related]

  • 4. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G, Toi M, Miceli R, Vermeulen PB, Dittadi R, Biganzoli E, Morabito A, Fanelli M, Gatti C, Suzuki H, Tominaga T, Dirix LY, Gion M.
    Cancer J Sci Am; 1999 Feb; 5(2):101-11. PubMed ID: 10198732
    [Abstract] [Full Text] [Related]

  • 5. [Adjuvant therapy of breast cancer].
    Semiglazov VF, Abzumanov AS, Bozhok AA, Ivanov VG, Ivanova OA, Barash NIu, Topuzov EE, Seleznev IK, Migmanova NSh, Popova RT, Nurgaziev KSh.
    Khirurgiia (Mosk); 2001 Feb; (5):52-60. PubMed ID: 11505673
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. One more change of paradigm in breast cancer treatment. Postmastectomy radiotherapy for patients with one to three lymph node metastases?
    Sautter-Bihl ML, Sauer R.
    Strahlenther Onkol; 2007 Jul; 183(7):357-9. PubMed ID: 17609867
    [No Abstract] [Full Text] [Related]

  • 8. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE, Green SJ, Lew D, Costanzi JJ, Athens JW, Osborne CK, Vaughn CB, Martino S.
    Cancer; 2003 Jan 01; 97(1):21-9. PubMed ID: 12491501
    [Abstract] [Full Text] [Related]

  • 9. [Breast carcinoma in accessory gland: a case report].
    Sivelli R, Del Rio P, Arcuri MF, Corcione L.
    G Chir; 2002 May 01; 23(5):179-80. PubMed ID: 12228967
    [Abstract] [Full Text] [Related]

  • 10. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC, Chen SC, Chang HK, Hsueh S, Tsai CS, Lo YF, Hwang TL, Chen MF.
    Jpn J Clin Oncol; 2005 Sep 01; 35(9):514-9. PubMed ID: 16199422
    [Abstract] [Full Text] [Related]

  • 11. [Recent advance in adjuvant therapy for breast cancer].
    Shimizu C, Watanabe T.
    Gan To Kagaku Ryoho; 2002 Dec 01; 29(13):2458-69. PubMed ID: 12506467
    [Abstract] [Full Text] [Related]

  • 12. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials.
    Overgaard M, Nielsen HM, Overgaard J.
    Radiother Oncol; 2007 Mar 01; 82(3):247-53. PubMed ID: 17306393
    [Abstract] [Full Text] [Related]

  • 13. [Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
    Ost E, Illiger HJ.
    Strahlenther Onkol; 2002 Jan 01; 178(1):54-5. PubMed ID: 11977396
    [No Abstract] [Full Text] [Related]

  • 14. [Prospective randomized trial on the efficacy of adjuvant endocrine therapy for ER-positive breast cancer patients after radical mastectomy].
    Jiang Z, Song S, Liu X.
    Zhonghua Zhong Liu Za Zhi; 2001 Sep 01; 23(5):420-2. PubMed ID: 11810777
    [Abstract] [Full Text] [Related]

  • 15. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
    International Breast Cancer Study GroupDivision of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. marco.colleoni@ieo.it, Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD.
    J Clin Oncol; 2006 Mar 20; 24(9):1332-41. PubMed ID: 16505417
    [Abstract] [Full Text] [Related]

  • 16. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
    Davidson NE, O'Neill AM, Vukov AM, Osborne CK, Martino S, White DR, Abeloff MD.
    J Clin Oncol; 2005 Sep 01; 23(25):5973-82. PubMed ID: 16087950
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Paradigm shift in adjuvant treatment of receptor positive premenopausal breast cancer patients? Not yet!
    Samur M, Bozcuk HS.
    J Clin Oncol; 2003 Jun 15; 21(12):2444; author reply 2445-7. PubMed ID: 12805349
    [No Abstract] [Full Text] [Related]

  • 19. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H, Skaland I, Varhaug JE, Kørner H, Janssen EA, Gudlaugsson E, Baak JP, Søreide JA.
    Acta Oncol; 2009 Jun 15; 48(4):514-21. PubMed ID: 19107621
    [Abstract] [Full Text] [Related]

  • 20. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
    Inaji H, Sakai K, Oka T, Ozawa K, Saito Y, Senoo T, Taguchi T, Terasawa T, Nakao K, Mori T, Koyama H, Oshima A.
    Gan To Kagaku Ryoho; 2006 Oct 15; 33(10):1423-9. PubMed ID: 17033231
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.